ERBB2 and breast carcinoma: While systemic deletion of Akt isoforms validated Akt1 as a suitable target for cancer therapy in hormone receptor-positive and HER2-enriched breast cancers, it remains to be seen how systemic deletion of Akt1, Akt2 and Akt3 in different subtypes of breast cancer affects breast cancer development and progression.